Bravado Pharmaceuticals
Bravado Pharmaceuticals is a contract development and manufacturing organization (CDMO) based in Lutz, Florida. The company provides end-to-end pharmaceutical development services from preformulation and analytical method development to pilot-scale and early-phase clinical manufacturing. Facilities include GMP-ready clean rooms for small-scale sterile production, controlled-environment equipment, and analytical laboratories supporting stability testing and regulatory-compliant workflows. The organization holds FDA, DEA and state registrations and operates as a 503B sterile compounding facility.
Industries
Nr. of Employees
small (1-50)
Bravado Pharmaceuticals
4212 Cypress Gulch Dr, Lutz, FL 33559
Products
Sterile nasal prophylaxis (antibody-based nasal drops for respiratory virus prevention)
Sterile nasal antibody formulation developed as a prophylactic to block viral entry via the nasal cavity; developed in collaboration with external research partners.
Hydrogels for endoscopic procedures
Development of hydrogel formulations intended for use in endoscopic clinical procedures.
Vaccine formulation formats (solution, suspension, lyophilized)
Formulation and development experience for vaccine presentations including solution, suspension and lyophilized forms.
Multi-layer and specialty tablet systems
Development experience with trilayer and multilayer tablet technologies for targeted release profiles across therapeutic areas (e.g., CNS, metabolic, urology).
Support for orally administered immunotherapy and implantable ocular products (development support)
Analytical and formulation development experience supporting oral immunotherapy products and intravitreal implant development.
Sterile nasal prophylaxis (antibody-based nasal drops for respiratory virus prevention)
Sterile nasal antibody formulation developed as a prophylactic to block viral entry via the nasal cavity; developed in collaboration with external research partners.
Hydrogels for endoscopic procedures
Development of hydrogel formulations intended for use in endoscopic clinical procedures.
Vaccine formulation formats (solution, suspension, lyophilized)
Formulation and development experience for vaccine presentations including solution, suspension and lyophilized forms.
Multi-layer and specialty tablet systems
Development experience with trilayer and multilayer tablet technologies for targeted release profiles across therapeutic areas (e.g., CNS, metabolic, urology).
Support for orally administered immunotherapy and implantable ocular products (development support)
Analytical and formulation development experience supporting oral immunotherapy products and intravitreal implant development.
Services
End-to-end pharmaceutical development from preformulation and analytical development through pilot-scale and early clinical manufacturing.
Aseptic and non-aseptic compounding for 503B outsourcing pharmacy requirements covering ophthalmic, injectable, nasal and other dosage forms.
API characterization, excipient compatibility, polymorph screening, particle sizing and formulation screening to support dosage-form selection and development.
Development and validation of stability-indicating methods, routine QC testing, dissolution and stability sample analysis to support product release and regulatory filings.
Small-batch manual packaging and unit-dose blister packaging to support clinical studies and stability programs.
Custom proposal development and program planning from project submission through execution, including cradle-to-grave planning for development and manufacture.
End-to-end pharmaceutical development from preformulation and analytical development through pilot-scale and early clinical manufacturing.
Aseptic and non-aseptic compounding for 503B outsourcing pharmacy requirements covering ophthalmic, injectable, nasal and other dosage forms.
API characterization, excipient compatibility, polymorph screening, particle sizing and formulation screening to support dosage-form selection and development.
Development and validation of stability-indicating methods, routine QC testing, dissolution and stability sample analysis to support product release and regulatory filings.
Small-batch manual packaging and unit-dose blister packaging to support clinical studies and stability programs.
Custom proposal development and program planning from project submission through execution, including cradle-to-grave planning for development and manufacture.
Expertise Areas
- Contract development and manufacturing (CDMO) services
- 503B sterile compounding and aseptic processing
- Formulation and process development for multiple dosage forms
- Analytical method development and QC testing
Key Technologies
- High-performance liquid chromatography (HPLC)
- Gas chromatography–mass spectrometry (GC-MS)
- Fourier-transform infrared spectroscopy (FTIR)
- Karl Fischer titration
News & Updates
Announcement of Michael Nguyen, PharmD joining the team to oversee sterile compounding and 503B operations.
Announcement noting Brian McMillan serves on the advisory board of an online graduate program in pharmaceutical chemistry at the University of Florida.
Announcement of Brian McMillan accepting a volunteer faculty appointment at the rank of Assistant Professor in a graduate pharmacy program.
Introduction to the company's leadership team highlighting experience across analytical, formulation, process development, manufacturing, QA and metrology.
Report on the company grand opening event and facility launch.
Announcement of Michael Nguyen, PharmD joining the team to oversee sterile compounding and 503B operations.
Announcement noting Brian McMillan serves on the advisory board of an online graduate program in pharmaceutical chemistry at the University of Florida.
Announcement of Brian McMillan accepting a volunteer faculty appointment at the rank of Assistant Professor in a graduate pharmacy program.
Introduction to the company's leadership team highlighting experience across analytical, formulation, process development, manufacturing, QA and metrology.
Report on the company grand opening event and facility launch.